CD274 and non-small cell lung carcinoma: The preliminary efficacy and safety of Tiragolumab plus atezolizumab as a first-line treatment in patients with PD-L1 high (TPS ≥50%) NSCLC observed in this phase 2 study is being confirmed in an ongoing phase 3 study (SKYSCRAPER-01; NCT04294810) which is expected to enroll 560 patients.